NEW YORK (GenomeWeb) – GNS Healthcare and the Multiple Myeloma Research Foundation announced today an agreement to use GNS' informatics solutions to explore genomic and clinical data from the Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile, or CoMMpass, study.
CoMMpass is an ongoing longitudinal study of 1,000 newly diagnosed patients with active multiple myeloma. Run by the MMRF, its objective is to map each of these patients’ genomic profiles to clinical outcomes to develop a more complete understanding of patient responses to treatments.
As part of this collaboration, GNS will use its reverse engineering and forward simulation technology inference engine to generate computer models based on data from the study's participants. The models could help researchers identify molecular pathways and targets that are involved in the disease's progression, novel potential therapeutic targets, and diagnostic biomarkers that could shed light on which treatments would work best for which patients, the partners said.
"Through creative, dynamic partnerships, we continually build new research models to accelerate development of the most promising treatments for patients with multiple myeloma," Walter Capone, president and CEO of the MMRF, said in a statement. "This collaboration with GNS to apply leading-edge computer models and analytics to uncover disease pathways in the diverse CoMMpass data set exemplifies this strategy."
Financial and other terms of the deal were not disclosed.